Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (URGN)
NASDAQ:URGN
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.8Last Year’s EPS
-0.97Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 10, 2025
|% Change Since: -1.53%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The call was generally positive, highlighting significant progress with the UGN-102 NDA submission, strong clinical trial results, and JELMYTO revenue growth. However, challenges include increased net loss and anticipated limitations in UGN-102's initial approval setting.Company Guidance
In the UroGen Pharma earnings call for the fourth quarter and full year 2024, the company provided detailed guidance and projections for 2025. Key metrics highlighted included anticipated full-year JELMYTO revenues between $94 million and $98 million, reflecting a year-over-year growth rate of 8% to 12% compared to 2024's $87.4 million in demand-driven revenues. Operating expenses for 2025 are forecasted to be in the range of $215 million to $225 million, inclusive of $11 million to $14 million in non-cash share-based compensation expenses. UroGen expects to ramp up its sales force from 52 to approximately 83 representatives in preparation for the potential launch of UGN-102, which boasts a significant market opportunity estimated at over $5 billion. The company also shared positive clinical trial outcomes, such as a complete response rate of 79.6% at three months and an 18-month duration of response at 80.6% for UGN-102. Additionally, UroGen reported a strong cash position of $241.7 million at the end of 2024, positioning them well for upcoming commercialization efforts and further R&D advancements.UGN-102 NDA Submission and FDA Review
UGN-102, aimed at treating intermediate risk, low-grade, non-muscle invasive bladder cancer, has been submitted for FDA review ahead of schedule, with a PDUFA target date of June 13.
Strong Phase 3 Trial Results
ENVISION Phase 3 trial data for UGN-102 showed a complete response rate of 79.6% at three months and 80.6% at 18 months, with a median duration of response not yet reached.
JELMYTO Revenue Growth
JELMYTO generated net product revenues of $90.4 million in 2024, up from $82.7 million in 2023, marking a 12% increase in underlying demand.
Acquisition of ICVB-1042
The acquisition of ICVB-1042, a next-generation oncolytic virus, aligns with UroGen's strategic focus and enhances its pipeline.
Strong Financial Position
UroGen ended 2024 with $241.7 million in cash, providing a solid foundation to continue executing strategic initiatives.
---
URGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
URGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 10, 2025 | $9.82 | $9.92 | +1.02% |
| Nov 06, 2024 | $12.21 | $12.24 | +0.25% |
| Aug 13, 2024 | $14.51 | $14.96 | +3.10% |
| May 13, 2024 | $12.74 | $13.07 | +2.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Urogen Pharma (URGN) report earnings?
Urogen Pharma (URGN) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Urogen Pharma (URGN) earnings time?
Urogen Pharma (URGN) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is URGN EPS forecast?
URGN EPS forecast for the fiscal quarter 2025 (Q1) is -0.8.
---